XML 55 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1

Revenues (Tables)

12 Months Ended

Dec. 31, 2024

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net product revenues consisted of the following for the years ended December 31:

						2024						2023
Products:
Kristalose						$	15,315,259					$	15,981,850
Sancuso						9,005,129						8,096,788
Vibativ						7,160,125						8,812,692
Caldolor						4,959,385						4,333,923
Acetadote						185,182						458,759
Omeclamox						(3,075)						20,030
Vaprisol						(174,538)						151,336
RediTrex						90,237						(341,886)
Total net product revenues						$	36,537,704					$	37,513,492

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration